Programme Speakers
Patrick Duxbury
Patrick Duxbury is a Partner at Wragge & Co LLP and Head of their Life Sciences Team. Patrick was originally a microbiologist and geneticist before re-qualifying as a lawyer in 1993 with First Class Honours.
Patrick specialises in all aspects of non-contentious intellectual property law in the life sciences sector. Recent transactions include several licensing and collaboration deals for biotech and pharmaceutical company clients such as BioXell, Cambridge Antibody Technology Group, Astex Therapeutics, Eisai, PanGenetics, Prosidion, The Wellcome Trust, Renovo and others. Patrick acted for BioXell in relation to their in-licensing transaction with Lay Line Genomics and he acted for Astex Therapeutics in their widely publicised licence and collaboration deals with AstraZeneca and Novartis last year. He also acted for Eisai on its recently announced acquisition of the European rights to the intrathecal painkiller, Prialt, from Elan and for The Wellcome Trust in its collaboration with GSK.
He has also advised in relation to recent fundraisings by Domantis and Chroma Therapeutics, the MBO by Close Brothers Private Equity of Rosemont Pharmaceuticals and on several spin outs for clients such as the Medical Research Council and Kings College London.
Patrick is on the editorial board of Pharmaceutical Law Insight and is a member of the Intellectual Property Committee of the ABPI.
